1 / 3

Ebola Vaccine Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals.

rajkumarbisen
Download Presentation

Ebola Vaccine Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ebola Vaccine Market - Global Industry Insights, Trends, Ebola Vaccine Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 Outlook, and Opportunity Analysis, 2018-2026 Ebola Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus disease, symptomatic treatment such as maintaining electrolyte balance, imagining required oxygen level, and treating infectious condition might help in improving patient’s health. Most of vaccines to prevent Ebola virus disease are under different developmental stage. Request Sample Copy of Research Report: Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1365 https://www.coherentmarketinsights.com/insight/request-sample/1365 Increasing number of Ebola cases in affected regions and new vaccine development for this are Increasing number of Ebola cases in affected regions and new vaccine development for this are expected to be factors driving growth of the market expected to be factors driving growth of the market Increasing mortality rates due to Ebola is expected to be a major factor for growth of the market. According to World Health Organization, in January 2018, around 50% people infected with EVD, have died. African countries such as Siberia, Sierra Leone, Guinea, Democratic Republic of Congo, Senegal, and Mali, Nigeria were affected with EVD. In 2014–16, outbreak in West African countries such as Siberia, Leone, and Guinea, lead to deaths of around 11,300 individuals. Some cases were observed during 2014–16 outbreak in the U.S., Spain, Italy, the U.K. among people that travelled to affected African countries and people who came in contact with infected patients. In May 2017, WHO declared outbreak of EVD in Democratic Republic of Congo. There is still fear about potential outbreak of EVC in vulnerable regions of Western Africa which earlier faced EVD outbreak due to gaps in public health infrastructure.Various institutes and pharmaceutical companies are focusing on developing vaccines against EVD. According to study published in the journal, The Lancet, in December 2016, rVSV-ZEBOV also known as V920 vaccine, which is jointly developed by Newlink Genetics and Merck and Company, was found to be effective in protection against EVD in phase three trial. rVSV-ZEBOV

  2. uses strain of Zaire Ebola virus. Merck is planning to file for final marketing approval of its EVD vaccine with the U.S. FDA in 2018. Moreover, it produced 3,00,000 vaccines, in case of fresh outbreak in vulnerable regions. Various key players are focusing on developing vaccines for EVD, in order to expand its market share. For instance, GlaxoSmithKline developed CAd3- ZEBOV vaccine, derived from chimpanzee adenovirus and was tested by National Institute of Allergic and Infectious Disease, which started its phase three trials in February 2016. Janssen Pharmaceutical’s Ad26-ZEBOV is an experimental vaccine under development and currently in phase one. In 2014, Novavax Inc. developed Ebola vaccine by using its proprietary recombinant technology. Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Ebola Vaccine Market Research Objective and Assumption • Ebola Vaccine Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Ebola Vaccine Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Ebola Vaccine Market, By Regions • Ebola Vaccine Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Ebola Vaccine Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Ebola Vaccine Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Ebola Vaccine Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Inquire Here Before Purchase: Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-to-analyst/1365 https://www.coherentmarketinsights.com/insight/talk-to-analyst/1365

  3. Key players in the global Ebola vaccine market are Merck and Company, Janssen Pharmaceutica Key players in the global Ebola vaccine market are Merck and Company, Janssen Pharmaceutica NV, GlaxoSmithKline, and Novavax Inc. NV, GlaxoSmithKline, and Novavax Inc. Ebola Vaccine Market Taxonomy: Ebola Vaccine Market Taxonomy: On the basis of virus strain, the global Ebola vaccine market is segmented into: • Recombinant vesicular stomatitis virus-Zaire Ebola virus • Chimpanzee Adeno virus type 3-Zaire Ebola virus • Adeno virus serotype 26- Zaire Ebola Virus About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: Email: sales@coherentmarketinsights.com sales@coherentmarketinsights.com

More Related